Quarterly venture investment activity into neurology focused biopharma companies is back to pre-2020 level. This is no surprise given the investment slowdowns across all therapy area and broader life sciences. The drop seems to have stabilized however, and emerging...
May 2023 Top Biopharma Deal: Cellular Biomedicine development and commercialization deal with Janssen for C-CAR039 and C-CAR066
Highlighted Deal Financial Comps
Total Deal Value:
Cost & Profit Split:
- Cellular Biomedicine granted Janssen exclusive, worldwide rights (excluding China) for the development and commercialization of C-CAR039 and C-CAR066 CAR-T therapies for Non-Hodgkin Lymphoma.
- Janssen has the option to develop therapies in China before the BLA application.
- Cellular will also transfer and supply the IND and studies with viral vector and plasmid related to C-CAR039 and C-CAR066.
- Cellular Biomedicine will receive an upfront payment of $245M, along with undisclosed potential milestone payments and royalties.
DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.
We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
Drug Sales Figures
All of this by stage, disease indication, modality, target...
More Research by DealForma
We are tracking the biopharma R&D partnerships in neurology through the first half of 2023. Some notable licensing deals include Voyager's partnership with Neurocrine, which secured an upfront payment of $175 million and the potential to achieve up to $4.2 billion...